Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers June 27, 2017
Pharmacy Choice - News - Front Page Healthcare News - June 27, 2017

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

Zydus Cadila Healthcare Ltd has received the final approval from the United States Food and Drug Administration for marketing Acamprosate calcium delayed release tablets 333 mg in the US. The tablet is used for maintenance of abstinence from alcohol in patients with alcohol dependence, said the company. The company will manufacture the tablets at i
5/27/17 - "Combination Pharmaceutical Composition and Methods of Treating Diseases Or Conditions Associated with Neurodegenerative Diseases" in Patent...
"Combination Pharmaceutical Composition and Methods of Treating Diseases Or Conditions Associated with Neurodegenerative Diseases" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventor Epshtein, Oleg Iliich, filed on January 3, 2017, was made available
5/27/17 - "Method for Preparing Azetidinone Compound and Intermediate of Azetidinone Compound" in Patent Application Approval Process (USPTO 20170121281)
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventors BAI, Hua; ZHAO, Xuyang; ZHANG, Yuncai; LI, Xufei; ZHANG, Yong; XU, Dezhou; ZHANG, Li; XU, Xiaojie; ZHU, Qifeng; WANG, Xiaoming; YANG, Zhiqing; ZHONG, Zehua; ZHANG, Jian, filed on June 5, 2015, was made available online on May 11, 2017, ac
5/27/17 - Abide Therapeutics Announces Dosing of First Subject in fMRI Imaging Study to Investigate Brain Activity Patterns Associated with ABX-1431
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Abide Therapeutics, a developer of innovative pharmaceuticals, announced initiation of dosing in a Phase 1 study using functional magnetic resonance imaging to evaluate patterns of neural activity in the brain associated with oral administration of ABX-1431, a first-in-class.
5/27/17 - Accelerated FDA approval and pricey drugs make a rotten combo, doctors argue [Tehran Times (Iran)]
Should drugs that win FDA approval on an accelerated pathoften without strong evidence of efficacycommand the same high prices as products that undergo the full menu of agency scrutiny? The ideaswhich include lower prices until drugs prove themselves out in confirmatory trialscome amid an unprecedented debate over the price tags on drugs in the U.S
5/27/17 - Analysis of the Congressional Budget Office's Estimate of the House-Passed Affordable Care Act Repeal Legislation
The AHCA would benefit wealthy households and insurance and drug companies at the expense of low and moderate-income individuals who would be harmed by radical cuts to Medicaid and much reduced premium tax credits to purchase health care in the Affordable Care Act's marketplaces. CBO/JCT project that losses will occur due to the proposal's repeal o
5/27/17 - ANOTHER OPINION CBO brutalizes GOP's health plan
There's no honor in keeping a promise to repeal the Obama law, which is how Lewis and others have defended their AHCA support, when the replacement would gut Medicaid, a safety-net program for children and the elderly, and would leave millions more Americans without health insurance. On Wednesday, the nonpartisan Congressional Budget Office release
5/27/17 - Attorney General Becerra Announces $33M Nationwide Settlement After Maker of Tylenol, Motrin, Benadryl Produced Adulterated Medicine
California Attorney General Xavier Becerra issued the following news release:. California Attorney General Xavier Becerra announced a $33 million settlement with drug manufacturer Johnson& Johnson after it violated federal regulations between 2009 and 2011 that ensure the quality of certain medicines, including many consumed by children.
5/27/17 - BioCryst gets a big boost from its latest HAE data, but it still faces a dangerous high wire act and giant rivals [Tehran Times (Iran)]
A little more than a year ago, shares of Research Triangle Park, NC- based BioCryst$ BCRX were crushed by a failed Phase II trial for their lead drug for hereditary angioedema, or HAE. Setbacks like that are not new for BioCryst. But the biotech turned to another HAE drug coming up the pipeline.
5/27/17 - Calcimedica gets fast track status for CRAC channel inhibitor `CM4620` to treat acute pancreatitis [Tehran Times (Iran)]
Privately-held CalciMedica, announced that it received Fast-Track designation from the US Food and Drug Administration for its lead clinical compound, CM4620, a novel, calcium release-activated calcium channel inhibitor, for the treatment of acute pancreatitis. "We are very pleased to receive Fast-Track designation for CM4620, which may allow us t
5/27/17 - Cancer scientist tries to help others as he battles his own Stage 4 cancer [The San Diego Union-Tribune]
The lanky, low-key and bearded Point Loma Heights resident has a doctorate in medicinal chemistry and is the co-inventor of Zykadia, an FDA- approved lung cancer drug made by his employer, the massive Switzerland- based pharmaceutical company, Novartis. Four years later, that personal project, with the help of the advocacy group Fight Colorectal Ca
5/27/17 - Challenging year as waits have increased
The Shrewsbury and Telford Hospital NHS Trust annual report gives an insight into the challenges experienced by the hospitals between March 2016 and March this year. About 80 per cent of A&E patients were admitted or discharged within four hours at Royal Shrewsbury Hospital and Telford's Princess Royal. Infections Simon Wright, chief executive of t
5/27/17 - Clinical Trial Management System Market has been evaluated as a growing market, expected to grow with CAGR of 15% by 2022
Global Clinical trial management system Market Information, By Type, By Application, By End Users- Forecast Till 2022. Market research future published a half-cooked research report on global clinical trial management system market. The global clinical trial management system market is expected to grow at a CAGR of 15% during the period 2016 to 202
5/27/17 - EDITORIAL: Hastening Obamacare's demise isn't a solution [The Kansas City Star]
May 27 Now that our area's top insurer, Blue Cross and Blue Shield of Kansas City, has announced that it is pulling out of the Affordable Care Act exchange next year, about 67,000 of its customers in Kansas and Missouri are vulnerable. Congressional Republicans insist that they don't want insurance markets here or anywhere else to fail. Roy Blunt
5/27/17 - EDITORIAL: State can't afford to go its own way on health care [The Press Democrat, Santa Rosa, Calif.]
May 27 The nonpartisan Congressional Budget Office's assessment of the latest Obamacare replacement bill is sobering: 14 million people would lose their health insurance in the first year, with the number ballooning to 23 million within a decade. Is it any wonder that GOP leaders jammed this bill through the House before the analysis was complete
5/27/17 - Establishment Labs Expands Management Team with Key Addition in Quality Assurance and Regulatory Affairs [Sudan Tribune]
-Establishment Labs, a global medical device company focused on aesthetic technologies with a strong emphasis on product development and innovation, announced today the expansion of its leadership team with the addition of Alberto Quesada as Vice President of Quality Assurance& Regulatory Affairs. His background and track record of achievement with
5/27/17 - FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson [T-break Tech (Middle East)]
Pfizers biosimilar to blockbuster anemia meds Epogen and Procrit won the support of an FDA expert panel on Thursday, moving another step closer to a potential approval. Indeed, ahead of the panels meeting, FDA reviewers called the Pfizer med highly similar to the reference product, epoetin alfa, sold by Amgen as Epogen and Johnson& Johnson under th
5/27/17 - Federal Contracts Awarded by Federal Agencies in Texas (May 27)
GRAND PRAIRIE, Texas, May 27 Correctional Diagnostic Imaging Inc., Lititz, Pennsylvania, won a federal contract set aside for small business valued at up to $1,336,994 from the U.S. Department of Justice's Bureau of Prisons for mobile onsite diagnostic testing services. FORT WORTH, Texas, May 27 7500 Viscount Partners, El Paso, Texas, won an $8
5/27/17 - Glenmark gets USFDA`s approval to sell generic blood pressure medicine [Sudan Tribune]
Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for its generic version Olmesartan Medoxomil Tablets, used in treatment of high blood pressure. The approval granted by the US Food and Drug Administration to Glenmark Pharmaceuticals Inc is for multiple strengths of 5 mg, 20 mg and 40 mg, the company sa
5/27/17 - Global Peptide Therapeutics Market & Clinical Trials Insights, 2022 [Sport360]
-Research and Markets has announced the addition of the "Global Peptide Therapeutics Market& Clinical Trials Insight 2022" report to their offering. Global Peptide Therapeutics Market& Clinical Trials Insight 2022 report gives comprehensive insight into the various clinical and non-clinical issues involved in the development of global peptide drug.
5/27/17 - Guangzhou receives Chinese approval for clinical trials of KX-02 for glioblastoma [Syrian Arab News Agency]
Athenex, a global specialty oncology pharmaceutical company focusing on the development and commercialization of next generation therapies for cancers and supportive therapies, announced that its partner, Guangzhou Xiangxue Pharmaceutical Co. Ltd., has received the Chinese FDA Investigational New Drug approval to begin clinical trials for KX-02...
5/27/17 - GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Groundbreaking Study of Epidiolex (cannabidiol) in The New England Journal of Medicine [Sudan Tribune]
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex in...
5/27/17 - Healthcare 21 signs new distribution agreement with German medical manufacturer for UK and Ireland [Syrian Arab News Agency]
Healthcare business Healthcare 21, which has its UK headquarters in Leeds, has entered into a long-term distribution agreement for the UK and Ireland with German medical device manufacturer, Medskin Solutions Suwelack AG. The healthcare distributor has signed the new partnership agreement with the biomedical skin and tissue specialist MedSkin...
5/27/17 - Insurance changes impact area residents [The Sedalia Democrat, Sedalia, Mo.]
May 27 On May 4, the U.S. House of Representatives voted 217 to 213 to repeal the Affordable Care Act of 2010, more commonly referred to as "ObamaCare." Area residents may see the impact of these decisions much sooner according to Joann Martin, administrator of the Pettis County Health Center. According to the Kansas City Star, that decision will
5/27/17 - Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement [Sport360]
-Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that, in order to replace its existing expiring shelf registration statement, it has filed a new shelf registration...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement